Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901172 | 0.85 | ALDH1A1 (0.76) | RAB9AALDH1A1HSD17B10CYP1A2POLB | |
| SCHEMBL19707566 | 0.83 | GAA (0.65) | GAARAB9AALDH1A1NPC1IDO1 | |
| SCHEMBL31256564 | 0.82 | RAB9A (0.59) | GAARAB9AALDH1A1NPC1TGM2 | |
| SCHEMBL7429227 | 0.82 | GAA (0.73) | GAARAB9AALDH1A1CYP1A2TGM2 | |
| SCHEMBL26038123 | 0.82 | TDP1 (0.68) | GAARAB9AALDH1A1NPC1TGM2 | |
| SCHEMBL25342519 | 0.82 | RAB9A (0.59) | GAARAB9AALDH1A1NPC1TGM2 | |
| SCHEMBL29893024 | 0.82 | GAA (0.73) | GAARAB9AALDH1A1CYP1A2TGM2 | |
| Acetanilide SCHEMBL28762299 | 0.82 | NAPRT (0.79) | GAARAB9AALDH1A1HSD17B10NPC1 | |
| SCHEMBL2090960 | 0.82 | GAA (0.62) | GAARAB9AALDH1A1NPC1IDO1 | |
| SCHEMBL1400845 | 0.82 | GAA (0.62) | GAARAB9AALDH1A1NPC1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433931-B2 | New method for the preparation of erlotinib | ITALIANA SINT SPA (IT) | 2016-11-02 | — | — | EP | claimed |
| US-8609841-B2 | Method for the preparation of erlotinib | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2013-12-17 | — | — | US | claimed |
| EP-2433931-B1 | New method for the preparation of erlotinib | ITALIANA SINT SPA (IT) | 2013-08-21 | — | — | EP | claimed |
| US-20120095228-A1 | METHOD FOR THE PREPARATION OF ERLOTINIB | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-04-19 | — | — | US | claimed |
| EP-2433931-A1 | New method for the preparation of erlotinib | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-03-28 | — | — | EP | claimed |
| EP-1885717-B1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX DELBRUECK CENTRUM (DE) | 2011-08-17 | — | — | EP | claimed |
| US-20080194563-A1 | Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1885717-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006128909-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2006-12-07 | — | — | WO | claimed |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | ORIGENIS GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12356795-B2 | Light emitting diode and display device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| CN-119775277-A | Compounds as modulators of LRRK2, NUAK1 and/or TYK2 kinases for the treatment of, for example, autoimmune diseases | 原真股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| US-4710468-A | FROM OPTICALLY ACTIVE SUBSTITUTED HYDROXYBUTYRIC ACID DERIVATIVES WITH OXIDOREDUCTASE | SIGMA-TAU INDUSTRIE PHARMACEUTICHE RIUNITE S.P.A. (IT) | 1987-12-01 | — | — | US | disclosed |
| EP-0138714-B1 | 1-(ACETYLAMINOPHENYL)-2-AMINO-PROPANONE DERIVATIVES, THEIR THERAPEUTICAL USE AND PROCESS FOR THEIR PREPARATION | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-05-20 | — | — | EP | disclosed |
| US-4642290-A | OXIDOREDUCTASE ENZYMES FERMENTING 4-SUBSTITUTED-ACETOACETIC ESTERS OR AMIDES | SIH CHARLES J (US) | 1987-02-10 | — | — | US | disclosed |
| EP-0138714-A2 | 1-(Acetylaminophenyl)-2-amino-propanone derivatives, their therapeutical use and process for their preparation | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194563-A1 | Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases | PTPN2, PTPRJ, PTPRS | GAA 2316/4885RAB9A 2407/4885ALDH1A1 3914/4885 |
| US-12356795-B2 | Light emitting diode and display device including the same | ALDH1A2, STRA6, DCX | GAA 2070/4885RAB9A 1567/4885ALDH1A1 96/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | GAA 1190/4885RAB9A 2340/4885ALDH1A1 3415/4885 |
| US-20120095228-A1 | METHOD FOR THE PREPARATION OF ERLOTINIB | EGFR, ABL1, ERBB2 | GAA 2039/4885RAB9A 960/4885ALDH1A1 823/4885 |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | NUAK1, TYK2, MARK1 | GAA 1225/4885RAB9A 592/4885ALDH1A1 2169/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | GAA 1225/4885RAB9A 592/4885ALDH1A1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.